MA32466B1 - Derives de triazole utiles pour le traitement de maladies - Google Patents

Derives de triazole utiles pour le traitement de maladies

Info

Publication number
MA32466B1
MA32466B1 MA33507A MA33507A MA32466B1 MA 32466 B1 MA32466 B1 MA 32466B1 MA 33507 A MA33507 A MA 33507A MA 33507 A MA33507 A MA 33507A MA 32466 B1 MA32466 B1 MA 32466B1
Authority
MA
Morocco
Prior art keywords
diseases
compounds
treatment
triazole derivatives
derivatives useful
Prior art date
Application number
MA33507A
Other languages
Arabic (ar)
English (en)
Inventor
Dannielle Frances Roberts
Lyn Howard Jones
Ross Sinclair Strang
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of MA32466B1 publication Critical patent/MA32466B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention porte sur des composés de formule (1) et sur des procédés permettant la préparation de ces composés, sur des intermédiaires utilisés pour la préparation de ces composés, sur des compositions contenant ces composés et sur leurs utilisations. Les composés selon la présente invention sont utiles dans de nombreuses maladies, troubles et états, en particulier des maladies, troubles et états inflammatoires, allergiques et respiratoires.
MA33507A 2008-07-11 2011-01-10 Derives de triazole utiles pour le traitement de maladies MA32466B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7983708P 2008-07-11 2008-07-11
PCT/IB2009/052986 WO2010004517A1 (fr) 2008-07-11 2009-07-09 Dérivés de triazole utiles pour le traitement de maladies

Publications (1)

Publication Number Publication Date
MA32466B1 true MA32466B1 (fr) 2011-07-03

Family

ID=41078162

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33507A MA32466B1 (fr) 2008-07-11 2011-01-10 Derives de triazole utiles pour le traitement de maladies

Country Status (29)

Country Link
US (1) US8263623B2 (fr)
EP (1) EP2300443B1 (fr)
JP (1) JP5608162B2 (fr)
KR (1) KR101235962B1 (fr)
CN (1) CN102089290B (fr)
AP (1) AP2010005508A0 (fr)
AR (1) AR072488A1 (fr)
AU (1) AU2009269610B2 (fr)
BR (1) BRPI0915897A2 (fr)
CA (1) CA2726686C (fr)
CO (1) CO6321248A2 (fr)
CR (1) CR11818A (fr)
DK (1) DK2300443T3 (fr)
DO (1) DOP2011000010A (fr)
EA (1) EA201001821A1 (fr)
EC (1) ECSP11010754A (fr)
ES (1) ES2398428T3 (fr)
IL (1) IL209730A (fr)
MA (1) MA32466B1 (fr)
MX (1) MX2011000352A (fr)
NI (1) NI201100006A (fr)
NZ (1) NZ589613A (fr)
PE (1) PE20110151A1 (fr)
SV (1) SV2011003802A (fr)
TW (1) TW201006822A (fr)
UA (1) UA99524C2 (fr)
UY (1) UY31976A (fr)
WO (1) WO2010004517A1 (fr)
ZA (1) ZA201100534B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011143106A1 (fr) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Composés pyrazolopyridiniques bifonctionnels
NZ603136A (en) 2010-05-10 2014-11-28 Gilead Sciences Inc Bifunctional quinoline derivatives
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (fr) 2010-05-13 2011-11-16 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agoniste bêta 2 adrénergique et antagoniste muscarinique m3
KR101840852B1 (ko) 2011-10-10 2018-03-22 삼성전자주식회사 모바일 장치의 표면 온도 관리 방법 및 멀티칩 패키지의 메모리 열관리 방법
KR101857529B1 (ko) 2011-11-08 2018-05-15 삼성전자주식회사 비휘발성 메모리 장치 및 그것의 구동 방법
EP2592078A1 (fr) 2011-11-11 2013-05-15 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agonistes bêta 2 adrénergique et antagoniste muscarinique M3
DE102012111829B4 (de) 2011-12-06 2024-10-10 Samsung Electronics Co., Ltd. Speichersysteme und Blockkopierverfahren davon
KR101859646B1 (ko) 2011-12-16 2018-05-18 삼성전자주식회사 보안 데이터를 보호하는 메모리 장치 및 보안 데이터를 이용한 데이터 보호 방법
DE102013100596B4 (de) 2012-01-27 2023-09-07 Samsung Electronics Co. Ltd. Nichtflüchtiges Speichersystem mit Programmier- und Löschverfahren und Blockverwaltungsverfahren
KR101903440B1 (ko) 2012-02-21 2018-10-02 삼성전자주식회사 비휘발성 메모리 장치 및 그것의 접지 선택 트랜지스터의 문턱전압 조절 방법
DE102013105356B4 (de) 2012-05-29 2026-05-21 Samsung Electronics Co., Ltd. Verfahren zum Betreiben von nichtflüchtigen Speichervorrichtungen, die effiziente Fehlererkennung unterstützen
KR101996004B1 (ko) 2012-05-29 2019-07-03 삼성전자주식회사 비휘발성 메모리 장치의 프로그램 방법 및 그것의 메모리 시스템
KR102000634B1 (ko) 2012-06-07 2019-07-16 삼성전자주식회사 비휘발성 메모리 장치 및 그것의 소거 방법
KR102025263B1 (ko) 2012-10-05 2019-09-25 삼성전자주식회사 메모리 시스템 및 그것의 읽기 교정 방법
KR102025251B1 (ko) 2012-10-31 2019-09-25 삼성전자주식회사 메모리 시스템 및 그것의 프로그램 방법
AU2013360866A1 (en) 2012-12-18 2015-07-02 Almirall, S.A. New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activity
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
KR102068342B1 (ko) 2013-03-07 2020-01-20 삼성전자주식회사 메모리 제어기 및 그것을 포함하는 메모리 시스템
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
KR102187643B1 (ko) 2013-12-04 2020-12-08 삼성전자주식회사 메모리 시스템 및 그것을 포함하는 유저 장치
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
JP6963616B2 (ja) * 2016-12-14 2021-11-10 ベイジン ショウバイ ファーマシューティカル カンパニー，リミティッド ４級アンモニウム塩構造を有する二官能性化合物
CN107194205B (zh) * 2017-05-31 2020-11-24 浙江大学 具有杀菌活性的jak2激酶抑制剂及其虚拟筛选方法
WO2019071144A1 (fr) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Utilisation d'inhibiteurs de p38 pour réduire l'expression de dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0823423B1 (fr) 1995-04-28 2004-06-16 Banyu Pharmaceutical Co., Ltd. Derives disubstitues en position 1,4 de piperidine
GB9603755D0 (en) 1996-02-22 1996-04-24 Pfizer Ltd Therapeutic agents
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CN1250545C (zh) 2000-12-28 2006-04-12 阿尔米雷尔普罗迪斯制药有限公司 新的奎宁环衍生物类及含有这类衍生物的药物组合物
DE10200943A1 (de) 2002-01-12 2003-07-24 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Scopinestern
US7232835B2 (en) 2002-12-10 2007-06-19 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
CN101239969B (zh) * 2003-02-14 2011-07-20 施万制药 联苯衍生物
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1460064A1 (fr) 2003-03-14 2004-09-22 Pfizer Limited Derivés de Indole-2-carboxamide comme beta-2 agonistes
WO2004089892A2 (fr) 2003-04-01 2004-10-21 Theravance, Inc. Diarylmethyle et composes apparentes
ATE435862T1 (de) 2003-05-28 2009-07-15 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
ES2289691T3 (es) 2004-01-22 2008-02-01 Pfizer, Inc. Derivados de sulfonamida para el tratamiento de enfermedades.
WO2005092840A1 (fr) 2004-03-23 2005-10-06 Pfizer Limited Derives de formamide utiles comme recepteurs adrenergiques
US7538141B2 (en) 2004-03-23 2009-05-26 Alan Daniel Brown Compounds for the treatment of diseases
WO2006023460A2 (fr) * 2004-08-16 2006-03-02 Theravance, Inc. Composes a activite agoniste pour recepteur ?2 adrenergique et antagoniste pour recepteur muscarinique
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
TW200745084A (en) * 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
JP2010501533A (ja) 2006-08-21 2010-01-21 アージェンタ ディスカバリー リミテッド Ｍ３レセプター調節物質として有用な窒素含有複素環化合物

Also Published As

Publication number Publication date
WO2010004517A1 (fr) 2010-01-14
MX2011000352A (es) 2011-02-22
CA2726686C (fr) 2014-03-11
NI201100006A (es) 2011-07-20
IL209730A (en) 2013-11-28
CO6321248A2 (es) 2011-09-20
AU2009269610B2 (en) 2012-02-02
AP2010005508A0 (en) 2010-12-31
US8263623B2 (en) 2012-09-11
EP2300443A1 (fr) 2011-03-30
PE20110151A1 (es) 2011-03-05
JP2011527672A (ja) 2011-11-04
JP5608162B2 (ja) 2014-10-15
US20100010040A1 (en) 2010-01-14
CN102089290B (zh) 2013-09-04
SV2011003802A (es) 2011-03-23
NZ589613A (en) 2012-06-29
UA99524C2 (ru) 2012-08-27
ECSP11010754A (es) 2011-02-28
HK1154382A1 (en) 2012-04-20
CR11818A (es) 2011-01-14
DK2300443T3 (da) 2013-02-18
UY31976A (es) 2010-02-26
KR20110018423A (ko) 2011-02-23
AR072488A1 (es) 2010-09-01
DOP2011000010A (es) 2011-01-31
AU2009269610A1 (en) 2010-01-14
CA2726686A1 (fr) 2010-01-14
EP2300443B1 (fr) 2012-12-12
BRPI0915897A2 (pt) 2015-11-03
ES2398428T3 (es) 2013-03-19
ZA201100534B (en) 2011-10-26
EA201001821A1 (ru) 2011-08-30
TW201006822A (en) 2010-02-16
IL209730A0 (en) 2011-02-28
KR101235962B1 (ko) 2013-02-21
CN102089290A (zh) 2011-06-08

Similar Documents

Publication Publication Date Title
MA30289B1 (fr) Dérivés d'amines
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA30778B1 (fr) Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
TNSN07022A1 (fr) Derives de pyridine
TN2009000450A1 (fr) Derives de pyridine
UA99524C2 (ru) Триазолопроизводные, полезные для лечения болезней
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
MXPA05012840A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades.
MA32965B1 (fr) Derives de sulfonamides
MA29926B1 (fr) Derives de pyrazine
MA33730B1 (fr) Procédés de synthèse pour des composés spiro-oxindoles
MA30405B1 (fr) Derives de 4-benzylphtalazinone substitues en 2 en tant qu'antagonistes des histamines hl et h3
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
TNSN07275A1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
TNSN04151A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA33155B1 (fr) Composes organiques et leurs utilisations
MY139690A (en) Sulfonamide derivatives for the treatment of diseases.